ATS 2018 International Conference - Mobile

Patient-Reported Outcomes of Long-Acting Muscarinic Antagonists (LAMA) or Long-Acting Beta2-Agonists (LABA) Monotherapy Versus LAMA/LABA Fixed Dose Combination (FDC) in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD) in the Real-World Setting: a Claims-Linked Survey Study [Board .

Location: Board no. 611

Session Type: RAPiD: Rapid Abstract Poster Discussion Session

Monday

May

21

2:15 PM

4:15 PM

Speaker(s)/Author(s)

Jonathan Kurlander

MS
Optum, Inc.

Eric T. Wittbrodt

Pharm.D., M.P.H.
AstraZeneca

Valery Walker

MS
Optum, Inc.

Maureen Carlyle

MPH
Optum, Inc.

Lauren Millette

Ph.D.
AstraZeneca

Junliang Tong

MS
Optum, Inc.

Michael DePietro

MD
AstraZeneca

View Abstract

Patient-Reported Outcomes of Long-Acting Muscarinic Antagonists (LAMA) or Long-Acting Beta2-Agonists (LABA) Monotherapy Versus LAMA/LABA Fixed Dose Combination (FDC) in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD) in the .

Parent Sessions

B102 - CLINICAL TRIALS AND STUDIES IN COPD...
05-21-2018 2:15 PM - 4:15 PM